Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:593658.
doi: 10.1155/2015/593658. Epub 2015 Feb 9.

Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma

Affiliations

Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma

Tatiana I Ivanova et al. Oxid Med Cell Longev. 2015.

Abstract

Genes encoding proteins with antioxidant properties may influence susceptibility to endometrial hyperplasia (EH) and endometrial carcinoma (ECa). Patients with EH (n = 89), EH concurrent with ECa (n = 76), ECa (n = 186), and healthy controls (n = 1110) were genotyped for five polymorphic variants in the genes involved in metabolism of lipoproteins (APOE Cys112Arg and Arg158Cys), iron (HFE Cys282Tyr and His63Asp), and catecholamines (COMT Val158Met). Patients and controls were matched by ethnicity (all Caucasians), age, body mass index (BMI), and incidence of hypertension and diabetes. The frequency of the APOE E 2 allele (158Cys) was higher in patients with EH + ECa than in controls (P = 0.0012, P(Bonferroni) = 0.018, OR = 2.58, 95% CI 1.49-4.45). The APOE E 4 allele (112Arg) was more frequently found in patients with EH than in controls and HFE minor allele G (63Asp) had a protective effect in the ECa group, though these results appeared to be nonsignificant after correction for multiple comparisons. The results of the study indicate that E 2 allele might be associated with concurrent occurrence of EH and ECa.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer Journal for Clinicians. 2011;61(2):69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Gallup D. G., Stock R. J. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstetrics and Gynecology. 1984;64(3):417–420. - PubMed
    1. Norris H. J., Tavassoli F. A., Kurman R. J. Endometrial hyperplasia and carcinoma. Diagnostic considerations. The American Journal of Surgical Pathology. 1983;7(8):839–847. doi: 10.1097/00000478-198307080-00012. - DOI - PubMed
    1. Podratz K. C., Mariani A., Webb M. J. Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecologic Oncology. 1998;70(2):163–164. doi: 10.1006/gyno.1998.5150. - DOI - PubMed
    1. MacKintosh M. L., Crosbie E. J. Obesity-driven endometrial cancer: is weight loss the answer? BJOG: An International Journal of Obstetrics & Gynaecology. 2013;120(7):791–794. doi: 10.1111/1471-0528.12106. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources